Presley Gerber’s death at a California rehab facility has raised serious concerns about overdose risks, withdrawal complications, and the overall safety of addiction recovery practices.
Presley Gerber, the son of model Cindy Crawford and businessman Rande Gerber, tragically passed away at the age of 27 while at a rehabilitation facility in California. His death has sparked urgent discussions regarding the risks associated with overdose, withdrawal complications, and the challenges faced in addiction recovery.
According to records from the Los Angeles County Medical Examiner’s Office, Gerber died on a Sunday, with confirmation of his passing provided by a representative for his mother. The family has requested privacy during this painful time, as they navigate their loss.
While the official cause of death has yet to be determined, audio recordings obtained by People indicate that a 911 call was made that morning reporting a cardiac arrest at the facility located on Berkeley Street. A separate dispatch suggested that the response was related to a potential overdose. The Medical Examiner’s Office has confirmed that an autopsy was performed, but the cause of death remains undetermined pending further testing.
Gerber had openly discussed his struggles with substance use and mental health issues in the past. Nicholas Kardaris, Ph.D., CEO and chief clinical officer of the New York Center for Living in Manhattan, spoke with Fox News Digital about the importance of understanding relapse, overdose risks, and the process of seeking help for loved ones dealing with addiction. Kardaris, who has no connection to Gerber’s case, cautioned against jumping to conclusions regarding the circumstances of his death.
Kardaris noted that individuals in residential treatment facilities often have complex medical histories, which may not be immediately apparent upon entering a program. He emphasized that younger individuals can sometimes experience sudden deaths, potentially due to underlying medical conditions that have gone undiagnosed.
“It’s not impossible to have a medication-related event, particularly if someone has an underlying heart disorder,” Kardaris explained. He added that certain medications can trigger cardiac episodes, highlighting the need for careful monitoring in treatment settings.
Entering treatment does not guarantee that a person’s issues have been resolved or that no risks exist. Kardaris pointed out that individuals seek rehabilitation because they are struggling with addiction, and this does not equate to being cured.
While treatment facilities strive to create a controlled environment, Kardaris acknowledged that they cannot eliminate all risks associated with addiction, withdrawal, relapse, or medical complications. “Facilities take great pains to make sure substances don’t come in, but it’s not a perfect system,” he said, noting that this observation applies generally to treatment settings and is not specific to Gerber’s case.
Withdrawal itself poses another significant risk during rehabilitation, with symptoms ranging from uncomfortable to life-threatening, depending on the substance involved and the individual’s level of physical dependence. Kardaris explained that withdrawal from benzodiazepines, such as Valium or Xanax, and alcohol can be particularly dangerous without proper medical supervision.
While opioid withdrawal can be extremely uncomfortable, it is generally not fatal on its own. However, the withdrawal from benzodiazepines can lead to severe complications, including seizures and delirium. Kardaris warned that individuals may disclose their use of heroin but might not mention concurrent withdrawal from benzodiazepines, which can lead to fatal outcomes if not properly managed.
Another critical point raised by Kardaris is that individuals with opioid use disorder may face heightened risks after detox. As their tolerance decreases, returning to a previously used amount can lead to overdose. “If someone relapses after rehab, they may use the same amount they were using before treatment — but their tolerance has gone down, and that amount can now be fatal,” he cautioned.
Gerber had previously shared on social media about undergoing ibogaine treatment in Mexico. Kardaris noted that ibogaine is not FDA-approved for any medical use in the United States. Although it has been studied as a potential treatment for opioid use disorder, its safety and effectiveness remain uncertain.
Kardaris categorized ibogaine alongside other psychoactive substances, such as ketamine and ayahuasca, which have gained popularity in recent years. While some research suggests potential benefits, these treatments remain largely unregulated. Ketamine is FDA-approved as an anesthetic but is not sanctioned for treating psychiatric disorders, although some clinicians use it off-label.
Overall, Kardaris described the current landscape of addiction treatment as “a bit of the Wild West,” emphasizing that Gerber’s prior ibogaine treatment does not provide insight into the substances he may have used or the cause of his death.
Families seeking treatment for loved ones should thoroughly investigate potential facilities, ensuring they are licensed and staffed by qualified medical professionals. Kardaris advised that families confirm the presence of appropriate protocols for withdrawal management and emergency situations.
“There are bad actors in every profession, so families should look for a well-regarded treatment program with qualified people who know what they’re doing,” he said, underscoring the importance of due diligence in selecting a treatment center.
The tragic passing of Presley Gerber serves as a sobering reminder of the complexities surrounding addiction recovery and the critical need for awareness and safety in treatment environments, according to Fox News Digital.